Clinical Trial Update: Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of zanubrutinib in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)

Snippet

Sponsor: BeiGene | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-25